Retatrutide + Cagrilintide
Also known as: Reta + Cagri, Triple-agonist + amylin blend
Pre-mixed metabolic blend combining retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, with cagrilintide, a long-acting amylin analog, both targeting appetite, satiety and energy balance for weight loss. Neither component is FDA-approved: retatrutide is in Eli Lilly's Phase 3 TRIUMPH program (NDA anticipated late 2026, approval not expected before 2027), and cagrilintide is investigational, studied mainly in Novo Nordisk's CagriSema combination. This specific blend is not an approved product and has no published controlled human efficacy or safety data; any rationale is inferred from the separate development-stage compounds, and combination-specific human data is lacking.
Who's worth your money for Retatrutide + Cagrilintide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
No sellers for Retatrutide + Cagrilintide are indexed yet — we add vendors and their prices as we find them.
Watch Retatrutide + Cagrilintide
Get one email when the market actually moves — no newsletter, no noise.
About Retatrutide + Cagrilintide
CAS
—
Molecular formula
—
Typical dose range
No validated or approved blend protocol exists. Investigational/vendor ranges for the components: retatrutide titrated from ~2 mg up toward 8–12 mg once weekly subcutaneous in trials; cagrilintide ~0.3–2.4 mg once weekly subcutaneous. Research use only — doses are not clinically established for the mixture.
Half-life
Component-dependent and not characterized for the mixture. Both retatrutide and cagrilintide are engineered for once-weekly dosing, consistent with multi-day plasma half-lives.
Common research uses
Safety notes
Not FDA-approved in any form; sold as a research/grey-market compound while both components remain investigational. No combination-specific human safety data. Known incretin- and amylin-class risks include nausea, vomiting and other GI effects, with retatrutide's glucagon agonism raising additional questions around heart rate and glucose handling under ongoing study. Stacking two appetite-suppressing agents may amplify GI and nutritional risks.
Reconstitution
Often supplied lyophilized; reconstitute with bacteriostatic water and refrigerate. As an unapproved investigational-peptide blend, dose accuracy, sterility and content of the combined compounds are not assured.
COAs for Retatrutide + Cagrilintide
5 third-party tests across 3 vendors. Each card links to the full report.
For
Retatrutide/Cagrilintide
by Glacier Aminos· batch RECA24GA-03
For
Retatrutide/Cagri Blend
by Simple Peptide· batch GRCG-032026-4
For
Retatrutide/Cagrilintide Blend
by Simple Peptide· batch RETCAG08272025-02
For
Retatrutide/Cagrilintide
by Glacier Aminos· batch RECA24GA01
Purity not on file
For
Retatrutide/Cagrilintide Blend
by EZ Peptides· batch EZP-RETCAG1503142026-03
9 citations indexed for Retatrutide + Cagrilintide
review · 2026
Beyond weight loss: multisystem benefits of obesity medications
Obesity is increasingly managed with medications as disease-modifying therapies, reflecting its role as a gateway disease driving metabolic, cardiovascular, reproductive, neuropsychiatric, and mechanical conditions.
review · 2026
Mechanotransduction of Collagen Biostimulators: Comparative Signaling and Implications for GLP‐1 RA–Associated Facial Aging
review · 2026
Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence
Objectives To investigate the association between anti-obesity medication (AOM) use and the risk of cognitive disorder in individuals with overweight and obesity.
review · 2026
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Anti-obesity medications (AOMs), led by the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide and the dual GIP/GLP-1 receptor agonist tirzepatide, have produced substantial weight reduction and growing signals of benefit that extend well beyond adiposity.
review · 2026
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Incretin-based therapies have transformed the management of obesity and type 2 diabetes mellitus (T2DM).
review · 2025
Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review
Obesity, a multifaceted and chronic condition characterized by excessive fat accumulation, poses significant risks to overall health and is associated with various metabolic and cardiovascular complications.
Research use only. Not for human consumption and not approved by the FDA. Nothing here is medical advice.